Oral Presentation Highlights the Results of a Phase II/III Trial of the Investigational Immunotherapy OBI-822/OBI-821 in Patients with Metastatic Breast Cancer
TAIPEI, TAIWAN, May 19, 2016 – OBI Pharma, Inc., a Taiwan biotech company (TPex: 4174), today announced that the company-sponsored abstract detailing the full results of its Phase II/III study of OBI-822/OBI-821 (formerly OPT-822/OPT-821) will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois to be held June 3-7, 2016.
The study evaluated the clinical benefit and immunogenicity of the investigational immunotherapy OBI-822 in patients with metastatic breast cancer. Detailed results of the study will be presented as an oral presentation.
The presenter will be Hope S. Rugo, MD, Professor of Medicine, Director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center. The first author of the abstract is Chiun-Sheng Huang, MD, PhD, Professor of Surgery and Director of the Breast Center at National Taiwan University Hospital.
“We are pleased to present these results at ASCO for our investigational immunotherapy OBI-822/821 for patients with metastatic breast cancer,” said Amy Huang, General Manager, OBI Pharma. “This allows us to showcase the meaningful work that OBI is doing in the oncology space. It is our hope that through this research we can better serve the needs of patients living with metastatic breast cancer.”
The following OBI-sponsored data will be presented at the 2016 ASCO Annual Meeting:
Oral Abstract Session: Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
- Abstract 1003: Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer
This abstract will be presented on Saturday, June 4, 2016 in Hall D2 from 2:15 PM – 2:27 PM by Hope S. Rugo, MDThe Abstract is accessible at this link: http://abstract.asco.org/176/AbstView_176_168513.html
A Chinese translation of the Abstract can be found here: http://www.obipharma.com/index.aspx?lang=chi&fn=news_content&no=72About OBI-822/OBI-821
OBI-822 is a new, investigational anti-cancer treatment that belongs to a novel class of active immunotherapies. It is a synthetic glycoprotein comprised of a Tumor-Associated Carbohydrate Antigen (TACA), Globo H, covalent bounded to a carrier protein, Keyhole Limpet Hemocyanin. OBI-821 is a saponin-based adjuvant. Globo H is expressed in high levels on the surface of malignant tumors in many epithelial cancers, such as breast, prostate, gastric, lung, colon, pancreatic, and ovarian cancer, etc. The immunogenicity of the antigen is enhanced by conjugating Globo H to the KLH carrier protein to form OBI-822 (Globo H-KLH), and co-administered with an adjuvant, OBI-821. It is exclusively licensed to OBI from Memorial Sloan-Kettering Cancer Center (MSKCC).
About OBI Pharmaceuticals
OBI Pharma, Inc. is a Taiwan biopharmaceutical company established in 2002. OBI’s mission is to develop novel therapeutic agents for unmet medical needs, including cancer and infectious diseases. The company’s flagship product is adagloxad simolenin (OBI-822), a first-in-class active immunotherapy for metastatic breast cancer. OBI is also developing next generation active immunotherapies for difficult to treat cancers, including lung, prostate, pancreatic, stomach, and ovarian. Additional information can be found at www.obipharma.com/en.
Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Exchange Commission.
OBI Pharma, Inc.
+886 (2) 2786-6589 x213